Abecma

{
  "id": "MLC-T-ONC-000100",
  "term": "Abecma",
  "field": "Oncology and biomedicine",
  "definition": "A treatment used for adults with multiple myeloma that came back or did not get better after treatment with at least two lines of anticancer therapy that included an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma is made using a patient’s T cells (a type of immune system cell). A gene for a special receptor called chimeric antigen receptor (CAR) is added to the T cells in the laboratory. These changed T cells called CAR T cells are grown in large numbers in the laboratory and given to the patient by infusion. Abecma binds to a protein called BCMA, which is found on myeloma cells and some types of immune cells. This helps the body’s immune system kill cancer cells. Abecma is a type of cellular immunotherapy called CAR T-cell therapy. Also called idecabtagene vicleucel.",
  "synonyms": [
    "idecabtagene vicleucel"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/abecma/"
}